Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

A robust Chemistry, Manufacturing, and Controls (CMC) strategy underpins a successful Investigational New Drug (IND) application for viral vector-based therapies. This requires a cohesive approach that aligns plasmid design, scalable vector production, and phase-appropriate analytics with global regulatory expectations. Our >100,000 sq ft facility is designed to support this integrated path, targeting an 18-24 month timeline to get candidates to IND. Franklin Biolabs provides the scientific and regulatory guidance necessary to build a data package that minimizes clinical risk and withstands agency scrutiny.

Aligning Manufacturing with Regulatory Expectations

Preparing a CMC data package for a viral vector requires a forward-looking strategy that anticipates regulatory questions. A successful submission is built on a foundation of well-characterized plasmids, a controlled manufacturing process, and a matrix of analytical methods that define the product’s identity, purity, and potency.

Our approach integrates these components into a single program. While the Franklin Biolabs brand launched in 2024, our scientific lineage has contributed to a 100% successful IND rate for sponsors since 2019, informing the strategic guidance required for regulatory submissions.

De-risking Vector Biology Through Analytical Rigor

Understanding a vector’s potential interaction with the immune system is a core component of the CMC package. The analytical methods must be sensitive enough to detect and quantify process-related impurities that could trigger an unwanted response.

• Insights from research identifying specific T-cell epitopes on viral capsids (PMID: 19777488) underscore the need for high-resolution purity assays. These methods must confirm the removal of residual host cell proteins and DNA that could contribute to immunogenicity.

• Similarly, understanding the mechanisms of immune tolerance induction by certain vectors (PMID: 23778424) informs the design of the potency assay matrix. The analytics must collectively demonstrate that the vector functions as intended without activating unintended biological pathways.

This data-driven approach yields a mechanistic understanding of the product, a level of detail highly valued by regulatory agencies.

The Plasmid-to-Product Continuum

The quality of the starting plasmid material directly impacts the quality of the final viral vector product, whether it is an Adeno-Associated Virus (AAV), Lentivirus (LV), or Adenovirus (AdV). A comprehensive CMC plan addresses the entire manufacturing lifecycle.

Key analytical checkpoints include:

• Plasmid Qualification: Verifying identity, purity, and integrity of all input plasmids (transgene, rep/cap, and helper).

• In-Process Controls: Monitoring key steps like transfection, harvest, and purification to ensure process consistency.

• Vector Titer & Potency: Employing orthogonal methods (e.g., ddPCR, ELISA, cell-based assays) to accurately quantify vector genome copies and biological activity.

• Purity & Impurity Profiling: Characterizing empty/full capsid ratios and quantifying process and product-related impurities.

This rigorous analytical framework provides the data necessary to justify product specifications and demonstrate manufacturing control for FDA and EMA submissions.